Wednesday , September 20 2017
Home / Biosimilars / Results from Late-Stage Study Demonstrate Clinical Equivalence of Boehringer Ingelheim’s Adalimumab Biosimilar Candidate to Humira

Results from Late-Stage Study Demonstrate Clinical Equivalence of Boehringer Ingelheim’s Adalimumab Biosimilar Candidate to Humira

Check Also

FDA Approves Amgen and Allergan’s Mvasi for the Treatment of Five Types of Cancer

THOUSAND OAKS, Calif., Sept. 14, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the U.S. …